Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR mutant non-small cell lung cancer (NSCLC) is limited by the development of drug resistance mutations, including the gatekeeper T790M mutation1-3. Strategies aimed at targeting EGFR T790M with irreversible inhi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Zhou, Wenjun, Ercan, Dalia, Chen, Liang, Yun, Cai-hong, Li, Danan, Capelletti, Marzia, Cortot, Alexis B., Chirieac, Lucian, Iacob, Roxana E., Padera, Robert, Engen, John R., Wong, Kwok-Kin, Eck, Michael J., Gray, Nathanael S., Jänne, Pasi A.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2879581/
https://ncbi.nlm.nih.gov/pubmed/20033049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature08622
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki